Form 4: Atara Biotherapeutics Officer Sells Shares for Tax
Insider Transaction Report
Atara Biotherapeutics' Chief Accounting Officer, Yanina Grant-Huerta, sold common stock to cover tax obligations related to vested restricted stock units.
Summary
- Yanina Grant-Huerta, Chief Accounting Officer of Atara Biotherapeutics, Inc. (ATRA), reported the sale of common stock.
- The transactions occurred on November 17, 2025.
- A total of 1,645 shares were sold at a weighted average price of $13.186 per share.
- An additional 85 shares were sold at a weighted average price of $13.188 per share.
- Another 74 shares were sold at a weighted average price of $13.191 per share.
- These sales were executed automatically to satisfy tax withholding obligations associated with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
- Following these transactions, Yanina Grant-Huerta beneficially owns 33,454 shares of common stock directly.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary sale of shares to cover tax obligations from vested restricted stock units, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This insider transaction is a routine, non-discretionary sale to cover tax obligations upon the vesting of restricted stock units, a common occurrence across all industries for executives receiving equity compensation. It does not reflect a change in the company's strategic direction or competitive position within the biotechnology sector.
Stakeholder Impact
- Shareholders: The sale is a routine tax-related transaction and is unlikely to have a significant impact on shareholder perception or the company's valuation.
- Employees: The transaction reflects a standard practice for equity compensation and tax management, which is common for employees receiving restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 11/17/2025 | Date of common stock transactions by Yanina Grant-Huerta. |
| 11/19/2025 | Date the Form 4 was signed and filed. |
Keywords
Atara Biotherapeutics, ATRA, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Chief Accounting Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.